This bill phases out enhanced federal funding for Medicaid in states that expanded coverage under the Affordable Care Act. It gradually reduces the federal share of Medicaid costs for states that expanded coverage, decreasing the percentage each year from 2027 through 2034 before returning to standard funding levels after 2035. The change directly affects low-income residents in expansion states who rely on Medicaid, as states will pay more for their coverage over time. Non-expansion states (those that haven't expanded Medicaid) are exempt from these reductions, and expansion states can choose to limit coverage to individuals at or below 100% of the federal poverty line to maintain the higher federal funding rate.
The ROOT Act (S 1692) requires doctors ordering outpatient imaging tests (like X-rays and MRIs) to use a tool that verifies test appropriateness starting January 1, 2026, with exceptions for preventive screenings (e.g., mammograms, lung cancer screenings), clinical trials, and small/rural practices. The tool must transmit data to Medicare, including the ordering doctor’s ID and test details, to track compliance. Medicare will identify doctors with low compliance rates (using the tool infrequently) and study how this affects imaging use, reporting findings to Congress every five years beginning in 2031.
S 1675 would amend federal death penalty law to add a new aggravating factor for capital sentencing. Specifically, it would allow the death penalty to be considered if a defendant is an alien who entered or remained in the U.S. illegally and was convicted of killing, attempting to kill, or conspiring to kill a U.S. citizen. This provision directly affects defendants in federal murder cases who meet both criteria: violating immigration laws and committing violent crimes against citizens. The bill changes sentencing guidelines by expanding the circumstances under which the death penalty could be applied.
This bill requires Medicare to cover "prescription digital therapeutics" (software-based treatments for medical conditions, like apps for diabetes management or mental health) starting January 1, 2026. It mandates Medicare to establish payment rules for manufacturers - considering actual costs and usage - and create specific billing codes for these tools. Manufacturers must annually report pricing, distribution volume, and user data to Medicare, with penalties for noncompliance. The bill directly affects Medicare beneficiaries, digital therapeutic developers, and healthcare providers who prescribe these digital health tools.
This bill increases tax deductions for small businesses and manufacturers by raising limits on expensing equipment and assets. It permanently extends a business interest deduction rule and boosts the Section 179 deduction cap from $1 million to $2.5 million (with the phaseout threshold rising from $2.5 million to $4 million). The changes apply to property placed in service after December 31, 2024, and include inflation adjustments starting in 2025. These provisions directly benefit eligible small businesses and manufacturers by reducing their taxable income when purchasing qualifying equipment.
The INDEX Act (S 1670) requires investment advisers managing passively tracked funds (like index funds) to vote proxy ballots according to their clients' instructions, directly affecting millions of retail investors who own these funds. It mandates that advisers vote shares proportionally based on client ownership percentages - e.g., if 20% of a fund's clients hold shares, their voting preference applies to 20% of the fund's votes. Exceptions allow advisers to vote "routine" matters (like board elections) without client input if instructions aren't received 10 days prior, or to mirror other shareholders' votes for majority-required proposals. The bill aims to align voting with investor preferences while prohibiting advisers from charging funds for compliance costs.
HR 3303, the America-Israel AI Cooperation Act, modifies U.S. export rules for advanced semiconductors to include Israel on the same regulatory list as other countries. It directs the Commerce Secretary to adjust the existing "Framework for Artificial Intelligence Diffusion" rule to ensure exports of controlled AI-related chips to Israel face identical requirements and exceptions as exports to other listed nations. This change directly affects U.S. semiconductor exporters and Israeli entities seeking to import these technologies. The bill does not create new restrictions but aligns Israel's export treatment with existing policy for other countries under the current regulatory framework.
HR 3277, the Ensuring Lasting Smiles Act, requires group health plans and health insurance issuers to cover medically necessary outpatient and inpatient treatments for congenital anomalies or birth defects primarily affecting the eyes, ears, teeth, mouth, or jaw. This includes reconstructive procedures, dental/orthodontic support during treatment, and follow-up care, but excludes purely cosmetic surgery not tied to a medical diagnosis. Cost-sharing (like copays) for these services must not be stricter than for other medical benefits. The law takes effect for plan years beginning January 1, 2026, and mandates insurers to provide notice about this coverage to beneficiaries.
The ETHIC Act (HR 3269) limits how many patents pharmaceutical companies can assert in lawsuits against generic drug and biosimilar manufacturers. Specifically, it prohibits a company from claiming more than one patent per "Patent Group" (commonly owned patents linked through disclaimers) in an infringement case involving a generic drug applicant or biosimilar product. This directly affects generic drug makers (under FDA's 505(b)(2) or 505(j) pathways) and biosimilar developers (under the Public Health Service Act), reducing the ability of brand-name companies to use stacked patents to delay competition. The law applies to applications submitted after its enactment date.
The Pregnancy.Gov Act requires the creation of a federal website, pregnancy.gov, to help pregnant and postpartum women find local resources. The website must allow users to search by ZIP code, filter services by distance (1-100 miles), and provide feedback on usability. It prohibits listing organizations that provide or support abortions (including abortion counseling, referrals, or financial support) and excludes such entities from receiving federal grants for resource aggregation. Within 180 days of launch, the government must report to Congress on website traffic, user experience, and gaps in available services, with multilingual access required.
This bill allows businesses to immediately deduct research and development (R&D) costs instead of spreading them over 60 months, directly benefiting companies investing in innovation. It increases the refundable R&D credit cap for small businesses from $250,000 to $750,000 over time, with specific phase-in amounts starting in 2025. Additionally, it expands access for startups by raising the gross receipts threshold for eligibility from $5 million to $15 million and increasing credit rates for qualified small businesses. These changes aim to make R&D tax incentives more accessible and valuable for smaller companies and new ventures.
This bill delays Medicare payment changes for ground ambulance services until 2028 and adds temporary rate increases during a transition period. It directly affects Medicare beneficiaries using ambulance services and ambulance providers who bill Medicare, particularly in rural areas. Key provisions extend the effective date for payment adjustments from October 2025 to January 2028 and establish temporary payment rates: 26.7% for super-rural ambulance services and 4.3% or 3.4% for regular ground ambulance services during the transition period (October 2025-January 2028). These changes aim to prevent sudden payment cuts that could disrupt access to ambulance care.
